Results 221 to 230 of about 152,178 (350)

PO60 THE ROLE OF LAPATINIB IN THE MANAGEMENT OF HER2-POSITIVE METASTATIC BREAST CANCER: A REVIEW OF A SINGLE INSTITUTION'S EXPERIENCE DURING THE TRASTUZUMAB AND LAPATINIB ERA

, 2015
Junichiro Watanabe, Satomo Matsuo
openalex   +1 more source

STAT3 activation confers trastuzumab‐emtansine (T‐DM1) resistance in HER2‐positive breast cancer [PDF]

, 2018
Lei Wang, Quanren Wang, Mingzhao Gao, Fu Li, Yun Li, Haitian Quan, Liguang Lou   +6 more
openalex   +1 more source

Reply to "Critical Evaluation of HER2 PET Imaging in Metastatic Breast Cancer: Addressing Key Challenges and Future Directions" and "The Role of HER2 PET in Treatment of Breast Cancer". [PDF]

J Nucl Med
Yeh R.
europepmc   +1 more source

KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer

, 2022
Keitaro Shimozaki, Eiji Shinozaki, Noriko Yamamoto, Yu Imamura, Hiroki Osumi, Izuma Nakayama, Takeru Wakatsuki, Akira Ooki, Daisuke Takahari, Mariko Ogura, Keisho Chin, Masayuki Watanabe, Kensei Yamaguchi   +12 more
openalex   +2 more sources

Antihypertensive Past Adherence Trajectories and Risk of Cardiotoxicity Among Adults Initiating Anthracycline Treatment

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 2, February 2026.
ABSTRACT Background Poor blood pressure control and low adherence to antihypertensives increase the risk for anthracycline‐induced cardiotoxicity (AIC) in hypertensive cancer patients. Little is known about whether past adherence to antihypertensive medications can reduce the risk of AIC in patients initiating anthracyclines.
Udim Damachi, Eberechukwu Onukwugha, Manu Murali Mysore, Wendy Camelo Castillo   +3 more
wiley   +1 more source

Tetravalent antibodies are more potent and efficacious erythropoiesis‐stimulating agents than erythropoietin in vivo

Protein Science, Volume 35, Issue 2, February 2026.
Abstract Recent studies have shown that tetravalent antibodies are potent and efficacious agonists of the erythropoietin (EPO) receptor (EPOR) both in vitro and in vivo. To identify antibody‐based erythropoiesis‐stimulating agents (ESAs) with therapeutic potential, we evaluated various tetravalent antibody formats for EPOR agonism and key biophysical ...
Jarrett J. Adams, Levi L. Blazer, Jacky Chung, Minoo Karimi, Taylor Davidson, Bailey Blair, Carlos Waddle, Craig A. Hokanson, Heather A. Bruce, Alexander U. Singer, Eva‐Maria Tombak, Kiira Gildemann, Nele Tamberg, Kaja Kiiver, Mart Ustav Jr, Yue Ma, Luigi Colombo, Lily Jun‐Shen Huang, Stephen W. Michnick, Orson W. Moe, Sachdev S. Sidhu   +20 more
wiley   +1 more source

Global Disproportionality Analysis of Adverse Event Reports on Interstitial Lung Diseases for Cancer‐Targeted Therapies, 1968–2024

Respirology, Volume 31, Issue 2, Page 152-161, February 2026.
ABSTRACT Background and Objectives The increasing complexity of interstitial lung disease (ILD) related to cancer‐targeted monoclonal antibodies (mAbs) has emerged as a significant clinical concern. Thus, this study aimed to investigate reporting signals of four ILD subtypes detected with cancer‐targeted mAbs.
Jinyoung Jeong, Hyunjee Kim, Sooji Lee, Jiyoung Hwang, Lee Smith, Ho Geol Woo, Jaehyeong Cho, Dong Keon Yon   +7 more
wiley   +1 more source

Anti-HER2-targeted therapies: effects on human <i>in vitro</i> blood-brain barrier models. [PDF]

Front Drug Deliv
Curtaz CJ, Gebert R, Wöckel A, Meybohm P, Burek M.   +4 more
europepmc   +1 more source

AGO Recommendations for Diagnosis and Treatment of Patients with Early and Metastatic Breast Cancer: Update 2012 [PDF]

, 2011
Harbeck, Nadia, Scharl, Anton, Thomssen, Christoph   +2 more
core   +2 more sources

MOESM6 of The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes

, 2017
Brian M. Necela, Bianca Axenfeld, Daniel Serie, Jennifer M. Kachergus, Edith A. Perez, E. Aubrey Thompson, Nadine Norton   +6 more
openalex   +1 more source